Compare BDN & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDN | YDES |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.3M | 543.0M |
| IPO Year | 1995 | 2024 |
| Metric | BDN | YDES |
|---|---|---|
| Price | $2.90 | $4.46 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 646.9K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | ★ 9.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $484,454,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.47 | $1.70 |
| 52 Week High | $4.41 | $22.00 |
| Indicator | BDN | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 47.86 |
| Support Level | $2.88 | $2.99 |
| Resistance Level | $3.31 | $5.15 |
| Average True Range (ATR) | 0.08 | 0.59 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 21.43 | 43.27 |
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.